Drug intelligence / Profile preview

dystrophin

Development stage: Preclinical
Lead developer: Evox Therapeutics
Modality: Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous, Oral, Subcutaneous

Overview

Dystrophin is a crucial protein involved in maintaining muscle cell integrity. Its absence or dysfunction leads to Duchenne muscular dystrophy (DMD), a severe muscle-wasting disease. As a therapeutic, dystrophin aims to replace the deficient protein in patients with DMD. Evox Therapeutics, with initial funding from Duchenne UK, explored using an exosome platform for delivering dystrophin as an alternative to viral gene therapies. Evox continued independent development after achieving initial proof-of-concept.

Targets

DMD (Dystrophin)

Beyond the preview

Go deeper on dystrophin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dystrophin.

Explore the full profile